The FDA approved Novartis’ $2.13 million gene therapy for spinal muscular atrophy on Friday. The treatment will cost $2.125 million — or $425,000 per year for five years.
In rationalizing the expensive price, Novartis said the one-time treatment costs 50% less than the 10-year cost of current chronic management for the disease.
"We believe by taking this responsible approach, we will help patients benefit from this transformative medical innovation and generate significant cost savings for the system over time," said Narasimhan, who hasThe Institute for Clinical and Economic Review, which evaluates drug prices, earlier this year said Zolgensma was worth up to only $1.5 million.
"Insurers were going to cover Zolgensma no matter the price, and Novartis has spoken publicly about considering prices that approached $5 million," ICER President Steven Pearson said in a statement. "It is a positive outcome for patients and the entire health system that Novartis instead chose to price Zolgensma at a level that more fairly aligns with the benefits for these children and their families.
"As a global leader in the treatment of spinal muscular atrophy, a life threatening, devastating disease, Biogen welcomes additional therapeutic options to help individuals with this rare disease," Biogen said in a statement. Acting FDA Commissioner Ned Sharpless lauded the approval, saying in a statement it marked "another milestone in the transformational power of gene and cell therapies to treat a wide range of diseases. With each new approval, we see this exciting area of science continue to move beyond the concept phase into reality."
इंडिया ताज़ा खबर, इंडिया मुख्य बातें
Similar News:आप इससे मिलती-जुलती खबरें भी पढ़ सकते हैं जिन्हें हमने अन्य समाचार स्रोतों से एकत्र किया है।
Monsanto faces thousands of Roundup-cancer lawsuits after $2 billion verdict“We’re not suing them for the fact that their product causes cancer. We’re suing them because they didn’t tell people that it causes cancer.”
और पढो »
RNC paid $2 million to law firm employing former White House counsel Donald McGahnThe RNC said the payment encompassed two years of work by the law firm Jones Day on a variety of matters.
और पढो »
Nascar to buy International Speedway in deal valued at $2 billion, at a 7% premium to original per-share bidInternational Speedway Corp. announced Wednesday a deal to be acquired by Nascar Holdings Inc. in a deal valued at $2.0 billion. Under terms of the deal,...
और पढो »
Infrastructure Week dies — again"There wasn’t going to be a $2 trillion deal anyway," Republican Rep. Sam Graves said.
और पढो »
Geoffrey Rush awarded $2 million in Sydney defamation caseOscar-winning actor Geoffrey Rush awarded $2 million in defamation case over reports he had been accused of inappropriate behavior toward an actress.
और पढो »
This $2 app changed the way I work.NBCNewsBETTER: With the Pomodoro Technique, you pick a task, set a timer for 25 minutes to work on that one thing, take a 5-minute break when the timer rings and repeat.
और पढो »
The FDA just approved a new treatment for a devastating disease. The price tag is more than $2 million.The treatment, called Zolgensma, should work longer than the typical drug, but also has a much higher price tag.
और पढो »
What it's like to shop at Grocery Outlet, the 'extreme value' supermarket that's been described as 'the TJMaxx of grocery stores'Grocery Outlet is a $2 billion supermarket chain with over 300 stores in California, Idaho, Nevada, Oregon, Pennsylvania, and Washington.
और पढो »